NCT04834349 2023-09-13
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute